Cavu Management, LP 的 Form 4 申報
Lantern Pharma Inc.（LTRN），2025/5/29 申報
- 申報編號
- 0001104659-25-054421
- 申報時間
- 2025/5/29 21:53 ET
- 交易日
- 2025/5/27-5/29
- 申報延遲
- 2 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 15 筆非衍生性交易。公開市場賣出合計 $16.8 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Cavu Management, LPCIK 0001813270 | 持股 10% 以上大股東 |
| Cavu Advisors, LLCCIK 0001813310 | 持股 10% 以上大股東 |
| BP Directors, LPCIK 0001813311 | 持股 10% 以上大股東 |
| Kreis Leslie W.CIK 0001813316 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/5/27 | Common Stock | S賣出處分 | −3,790 | $3.05F1 | −$11,559.5 | 213,763 | 間接 | |
| 2025/5/28 | Common Stock | S賣出處分 | −2,702 | $2.87F2 | −$7,754.74 | 211,061 | 間接 | |
| 2025/5/29 | Common Stock | S賣出處分 | −3,639 | $3.03F3 | −$11,026.17 | 207,422 | 間接 | |
| 2025/5/27 | Common Stock | S賣出處分 | −6,479 | $3.05F1 | −$19,760.95 | 365,471 | 間接 | |
| 2025/5/28 | Common Stock | S賣出處分 | −4,620 | $2.87F2 | −$13,259.4 | 360,851 | 間接 | |
| 2025/5/29 | Common Stock | S賣出處分 | −6,221 | $3.03F3 | −$18,849.63 | 354,630 | 間接 | |
| 2025/5/27 | Common Stock | S賣出處分 | −1,000 | $3.05F1 | −$3,050 | 56,467 | 間接 | |
| 2025/5/28 | Common Stock | S賣出處分 | −714 | $2.87F2 | −$2,049.18 | 55,753 | 間接 | |
| 2025/5/29 | Common Stock | S賣出處分 | −961 | $3.03F3 | −$2,911.83 | 54,792 | 間接 | |
| 2025/5/27 | Common Stock | S賣出處分 | −7,478 | $3.05F1 | −$22,807.9 | 421,808 | 間接 | |
| 2025/5/28 | Common Stock | S賣出處分 | −5,332 | $2.87F2 | −$15,302.84 | 416,476 | 間接 | |
| 2025/5/29 | Common Stock | S賣出處分 | −7,180 | $3.03F3 | −$21,755.4 | 409,296 | 間接 | |
| 2025/5/27 | Common Stock | S賣出處分 | −2,290 | $3.05F1 | −$6,984.5 | 129,163 | 間接 | |
| 2025/5/28 | Common Stock | S賣出處分 | −1,632 | $2.87F2 | −$4,683.84 | 127,531 | 間接 | |
| 2025/5/29 | Common Stock | S賣出處分 | −2,199 | $3.03F3 | −$6,662.97 | 125,332 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
表 I 有 5 筆交易的價格引用這則附註。
- F2
The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive.
表 I 有 5 筆交易的價格引用這則附註。
- F3
The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive.
表 I 有 5 筆交易的價格引用這則附註。
備註
Exhibit 24 - Power of Attorney. This Form 4 is the second of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The first Form 4 was filed by Aaron Glenn Louis Fletcher as the designated filer.